Risdiplam is the only orally administered drug permitted with the treatment of SMA. It was FDA approved in 2020 to be used in sufferers two months of age and more mature, and it functions as an SMN2 gene splicing modifier leading to larger amounts of SMN protein. Oral administration is https://charlesb974quy7.blog-eye.com/profile